Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01335477 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT01335477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01335477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2011
Completion date
October 31, 2013
Enrollment
551 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary fibrosis